Department of Surgery (Plastic), Yale School of Medicine, Yale University, New Haven, CT, USA.
Department of Biomedical Engineering, Yale University, New Haven, CT, USA.
Methods Mol Biol. 2022;2549:259-269. doi: 10.1007/7651_2021_378.
iPSC technology is revolutionizing the field of regenerative medicine. The generation of patient-specific cells has huge potential for disease modeling as well as for clinical applications. iPSCs have been used as a renewable source of vascular cells, and in particular vascular smooth muscle cells. The use of these human iPSC-derived vascular smooth muscle cells is attractive for vascular tissue engineering. The cells are used in developing vascular grafts as well as in engineering disease models. Recent studies have shown the proangiogenic potentials of human iPSC-derived vascular smooth muscle cells in treating wounds. Here, we describe the VSMC differentiation protocol from human iPSCs and encapsulation methods in collagen scaffolds to promote proangiogenic potentials.
iPSC 技术正在彻底改变再生医学领域。生成患者特异性细胞在疾病建模以及临床应用方面具有巨大的潜力。iPSC 已被用作血管细胞的可再生来源，特别是血管平滑肌细胞。这些源自人类 iPSC 的血管平滑肌细胞的使用对于血管组织工程具有吸引力。这些细胞用于开发血管移植物以及工程疾病模型。最近的研究表明，源自人类 iPSC 的血管平滑肌细胞在治疗伤口方面具有促血管生成潜力。在这里，我们描述了从人类 iPSC 中分化血管平滑肌细胞的方案以及在胶原支架中包埋的方法，以促进其促血管生成潜力。
